Home > Insider Trading > Filing (0001178913-20-001490)

Filing Details

Accession Number:: 0001178913-20-001490
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-05-14 20:30:57
Reporting Period:: 2020-05-12

Accepted Time:: 2020-05-14 20:30:57
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1797336	Ayala Pharmaceuticals Inc.	AYLA	()	L3

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1429390	Ltd. Services Financial & Investments Insurance Harel	3 Aba Hillel Road Street Ramat Gan L3 52118		No	No	Yes	No
1666482	Harel Insurance Co Ltd	3 Aba Hillel Road Street Ramat Gan L3 52118		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, Par Value $0.01 Per Share	Acquisiton	2020-05-12	307,692	$0.00	1,402,077	No	4	C	Indirect	See footnote
Common Stock, Par Value $0.01 Per Share	Acquisiton	2020-05-12	211,757	$0.00	1,613,834	No	4	C	Indirect	See footnote
Common Stock, Par Value $0.01 Per Share	Acquisiton	2020-05-12	50,000	$15.00	1,663,834	No	4	P	Indirect	See footnote
Common Stock, Par Value $0.01 Per Share	Acquisiton	2020-05-12	500,000	$15.00	2,163,834	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock, par value $0.01 per share	Disposition	2020-05-12	307,692	$0.00	307,692	$0.00
Common Stock	Series B Preferred Stock, par value $0.01 per share	Disposition	2020-05-12	211,757	$0.00	307,692	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

Upon the closing of the Issuer's initial public offering on May 12, 2020, each share of Series A Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") of the Issuer immediately converted into one share of Common Stock of the Issuer in accordance with the terms of the Issuer's Amended and Restated Certificate of Incorporation. Each share of Preferred Stock was convertible at any time, at the holder's election, and automatically upon consummation of the Issuer's initial public offering and had no expiration date. Share numbers of Preferred Stock in this Statement give effect to the reverse split of each share of the Issuer's Common Stock into 0.5 shares of Common Stock, which was effective for the shares of Preferred Stock upon their conversion into Common Stock upon the closing of the Issuer's initial public offering.
All of the shares of Common Stock reported in this row are (and all of the Preferred Stock reported in this Statement were) directly held by Harel Insurance Company Ltd. ("Harel Insurance"), a wholly owned subsidiary of Harel Insurance Investments & Financial Services Ltd. ("Harel Holdings"), for Harel Insurance's own account. While Harel Insurance operates under independent management and makes independent voting and investment decisions, Harel Holdings may be deemed, by virtue of its ownership of Harel Insurance, to both beneficially own and have a pecuniary interest in all shares presently directly owned by Harel Insurance for Harel Insurance's own account.
Shares acquired upon the closing of the Issuer's initial public offering at the initial public offering price of $15.00 per share.
All of the shares of Common Stock reported in this row were acquired and are held for members of the public through, among others, provident funds and/or mutual funds and/or pension funds and/or insurance policies and/or exchange traded funds, which are managed by wholly owned subsidiaries of the Reporting Persons, each of which subsidiaries operates under independent management and makes independent voting and investment decisions. Consequently, (i) this Statement shall not be construed as an admission by the Reporting Persons that they are the beneficial owners of more than 1,663,834 shares of Common Stock reported in this Statement, except to the extent of their pecuniary interest therein and (ii) this joint filing shall not be deemed an affirmation that a group exists among the Reporting Persons for the purposes of the Securities Exchange Act of 1934 or for any other purpose.